

From: [REDACTED] [REDACTED]  
Sent: 30 March 2009 10:39  
To: David Bevan  
Subject: NICE APPRAISAL: Rituximab for first line chronic lymphocytic leukaemia - ACD

Dear David  
Please ignore the email that I just sent you.

The Royal College of Pathologists and the BSH have one point to make about the Rituximab for first line chronic lymphocytic leukaemia ACD.

Comments:

Although it is uncontroversial that we should currently not be using rituximab in combination with chlorambucil outside of trials, this situation is likely to change within a relatively short time frame. However, the wording of the ACD is quite strong and will prevent rituximab being used with other chemo even when supporting data become available, and this would not be in the interests of CLL patients. With the ACD phrased as it is, I think NICE have a responsibility to revisit the topic as soon as the R-chlorambucil data are available.

Regards  
[REDACTED]